Long-term Nocturnal Calcium Infusions Can Cure Rickets and Promote Normal Mineralization in Hereditary Resistance to 1,25-Dihydroxyvitamin D

Sonia Balsan, Michèle Garabédian, Michel Larchet, Anne-Marie Gorski, Giulia Cournot, Cristina Tau, Agnès Bourdeau, Caroline Slive, and Claude Ricour
Laboratoire des Tissus Calcinés (Centre National de la Recherche Scientifique UA.583-Institut National de la Santé et de la Recherche Medicale U.30) and Department of Pediatric Gastroenterology, Hôpital des Enfants-Malades, 75015 Paris, France

Abstract

We report the beneficial effects of calcium infusions in a child with hereditary resistance to 1,25(OH)2D and alopecia. This patient after transient responsiveness to vitamin D derivatives became unresponsive to all therapy despite serum 1,25(OH)2D concentrations maintained at levels ~100-fold normal. A 7-mo trial with calcium infusions led to correction of biochemical abnormalities and healing of rickets. Bone biopsies (n = 3) showed a normal mineralization and the disappearance of the osteomalacia. Cultures of bone-derived cells demonstrated a lack of activation of 25-hydroxyvitamin D 24-hydroxylase and osteocalcin synthesis by 1,25(OH)2D3 (10-8 and 10-4 M). These results demonstrate that (a) even in the absence of a normal 1,25(OH)2D3 receptor-effector system in bone cells, normal mineralization can be achieved in humans if adequate serum calcium and phosphorus concentrations are maintained; and (b) calcium infusions may be an efficient alternative for the management of patients with this condition who are unresponsive to large doses of vitamin D derivatives.

Introduction

Hereditary resistance to 1,25-dihydroxyvitamin D (1,25(OH)2D), also termed vitamin D dependency type II, vitamin D-dependent rickets type II, or pseudo-vitamin D deficiency type II, is a rare condition characterized by rickets and/or osteomalacia that persist despite high circulating levels of 1,25(OH)2D (1). The underlying defects leading to the resistance of target cells to 1,25(OH)2D have not yet been identified. Results of a recent study, in which skin fibroblast extracts from eight such patients were evaluated for the detection and quantitation of 1,25(OH)2D3 receptors using a monoclonal antibody to the chick receptor molecule, suggest that resistance to the hormonal form of the vitamin is the consequence of structural variations in the receptor molecule and is not due to defective receptor synthesis (2). Whatever the basic molecular defect(s), the accumulating data clearly show a great heterogeneity in the clinical features of patients with hereditary resistance to 1,25(OH)2D and in their response to therapy with vitamin D derivatives (1). Favorable clinical responses to the administration of pharmacological doses of native vitamin D, 25(OH)D3, 1α(OH)D3, 1,25(OH)2D3 (3-10), or 24,25(OH)2D3 (11) have been reported in some patients. However, it has been shown that other patients with resistance to 1,25(OH)2D may remain unresponsive to similar therapeutic trials (10, 12, 13) or, after prolonged remission of their symptoms, become completely refractory to treatment with vitamin D derivatives (10). The absence of effective therapy may have severe consequences, especially in children. Death during the first three years of life, mainly due to pulmonary complications or hypocalcemic convulsions, has been reported in six children belonging to three affected kindreds (10, 11). Dwarfism, skeletal deformities, myopathy, and bone pain may seriously handicap such patients (10, 14).

A new model for the management of patient with hereditary resistance to 1,25(OH)2D unresponsive to large doses of vitamin D derivatives is described in the present report. The evaluation of 1,25(OH)2D3 action in cultured bone-derived cells obtained from our patient at the time this treatment was initiated and 3 mo after cessation of this therapy has provided the first demonstration that, in humans, normal mineralization can be achieved even in the absence of a normal 1,25(OH)2D receptor-effector system in bone cells.

Methods

Patient and treatment regimens. The detailed case history of patient A up to the age of 8 yr, from November 1974 to May 1983, has been previously reported (10). This child, born in 1974 to consanguineous parents, had congenital alopecia, and indications of rickets were first seen on radiographs when she was aged 7 mo. Three of her seven siblings had previously died at ~3 yr of age with alopecia and rickets resistant to vitamin D. During high-dosage therapy with vitamin D derivatives, patient A’s clinical course could be divided into three phases. Up to 3-yr-old, her rickets was active, with persistant hypocalcemia, hypophosphatemia and secondary hyperparathyroidism, in spite of high-dosage therapy with vitamin D3 (3 mg/d) or 25(OH)D3 (1 mg/d). The patient then entered a recovery phase. This phase was characterized by symptomatic improvement while on 1.5 mg/d of 25(OH)D3, followed by correction of her biochemical abnormalities, healing of rickets, and catch-up growth with therapy of 4-8 µg/d of 1α(OH)D3. At the age of 6 yr, she again showed hypophosphatemia, increased serum alkaline phosphatase, and radiographic rickets. This relapse continued over the ensuing 3 yr despite administration of up to 20 µg/d of 1α(OH)D3, 10 µg/d of 1,25(OH)2D3, and 5 µg/d of 25(OH)D3. Therapy with 25(OH)D3 induced an increase in serum 1,25(OH)2D levels, i.e., 11,012±4,487 pg/ml (mean±1 SD of 14 determinations). 25(OH)D3 therapy was stopped in September 1983. 3 mo later, the child was started on a high-calcium high-lactose diet. After 5.5 mo of this regimen the patient was once more placed on a normal calcium diet and a program of nocturnal calcium infusions was begun on the 17th of May 1984. The high-calcium high-lactose diet was obtained by enriching the usual normal diet of the child with dairy products (e.g., addition of powdered defatted milk to whole milk). This regimen was associated with oral supplements of 1 g/d of
calcium carbonate tablets and 20 g/d of lactose. Her calculated daily
intakes of calcium, phosphorus, and lactose were 2,250 mg, 1,610 mg,
and 62–82 g, respectively. For the intermittent parenteral calcium infusion
program, an intracaval catheter was inserted under general anesthesia.
The calcium solution, i.e., 500–1,000 mg of elemental calcium as calcium
 glucon-galactogluconate (calcium-Sandoz ampoules, Sandoz Laborato-
tories, Rueil Malmaison, France) in 500 ml of 5% dextrose, was infused
from 0800 p.m. to 0800 a.m., using a peristaltic pump. The amount of
 elemental calcium infused was progressively increased from 500 mg to
1,000 mg over the first 10 d of nocturnal calcium infusions; this dosage
was maintained for 1 mo. The patient subsequently received 750 mg
elemental calcium per 12 h daily for the next 4 mo. Thereafter, the
treatment was continued on a thrice-weekly infusion program providing
750 mg of elemental calcium per infusion. At the end of ~6 mo of
intracaval infusions the catheter was withdrawn and the thrice-weekly
nocturnal infusion therapy was continued using an arteriogenous fistula
that had been created in her left forearm under general anesthesia. The
calcium infusions were stopped after a total period of 7 mo.

Laboratory. Most chemical parameters were measured using auto-
matic clinical analysers (SMA 6 60 and AA II Technicon, Domont,
France). Measurements of serum calcium were carried out by atomic
absorption spectrophotometry (model 403, Perkin-Elmer Corp., Norwalk,
CT) and serum alkaline phosphatase activity was measured using two
techniques adapted to a spectrophotometer (Eppendorf Gerätebau,
Hamburg, model 6121, Federal Republic of Germany) or to an autoan-
alyzer (Vitatron AKS, Malakoff, France). Normal ranges were 2.25–
2.60 mmol/liter for calcium, and 90–300 IU/liter or 1,500–5,000 nkat/
liter for alkaline phosphatase (15). Qualitative and quantitative analyses
of amino acids in serum and protein-free urines were made with an
amino acid analyzer (TSIM 1 Technicon, Domont, France). Serum im-
munoreactive parathyroid hormone (iPTH) was measured by a modi-
fication of the method of Arnaud et al. (16) using two different antibovine
parathyroid hormone-(PTH) sera. Values are expressed as purified bovine
PTH equivalents. With the first antiserum, CgP, raised in our laboratory,
the lower limit of detection was 0.05 ng/ml. Values in normal children
and adults was <0.5 ng/ml; with the second antiserum kindly supplied
by Dr. J. Gueris (Hôpital Lariboisière, Paris, France), the lower limit of
detection was 5 ng/ml and the normal range 15–60 pg/ml. Serum
24(OH)D3 concentration was measured using the technique of Preece et
al. (17). Serum 24,25(OH)2D3 and 1,25(OH)2D3 were measured according
to Shepard et al. (18). The concentration determined by these techniques
corresponds to the sum of the vitamin D3 and D2 forms of each metab-
olite. The normal ranges for children in northern France are: 6–30 ng/
ml for 25(OH)D3, 1–3 ng/ml for 24,25(OH)2D3 and 20–80 pg/ml in chil-

Bone studies. Bone specimens were obtained from anterior iliac crests
with the trepene of Border. Three biopsies were performed while the
child was under general anesthesia for required surgical procedures, i.e.,
insertion of intracaval catheter, creation of an arteriogenous fistula, sur-
gical repair of this fistula. Each bone specimen was cut longitudinally in
half using a sharp lancet; one half was processed for quantitative histology,
and the other used for bone-derived cell cultures.

(a) Histomorphometry. The samples were fixed in a cacodylate-buff-
ered solution of glutaraldehyde (2.5%) and formaldehyde and embedded
in methyImetacyrlate without prior decalcification. 5- and 10-μm thick
sections were cut with a microtome (A. O. Spencer, Buffalo, NY) equipped
with a tungsten-carbide cutting edge and stained with toluidine blue (pH
6.4) or examined, unstained, by fluorescent microscopy under a Zeiss
Universal microscope. Morphometric data were obtained with a Zeiss
Morphomat 10 at x 200 magnification for volume data, and at x 500 magnification
for other parameters studied. The following measure-
ments were made. Bone volume, expressed as the percent of spongosia
volume composed of mineralized and nonmineralized bone matrix; os-
toid volume, as the percent of bone volume composed of osteoid tissue;
osteoid surface, as the percent of trabecular surface covered by osteoid
tissue; mineralization front, as the percent of osteoid surface showing a
thin band of fine granules at the limit between mineralized and non-
mineralized matrix on toluidine stained sections (at the pH used for the
staining solution the values obtained by this method correlate closely
with those obtained by tetracyline labeling (19)). Osteoblast surface
was calculated as the percent of trabecular surface covered by osteoblasts;
osteoclast/mm2, as the number of osteoclasts per square mm of section
surface. A tetracycline double labeling was performed before the third
biopsy with 1 g/24 h of tetracycline chloride administered according to
the following schedule: 2 d on, 6 d off, followed by 2 d on. The biopsy
specimen was taken 1 d after the last tetracycline intake. The mineral-
ization rate was assessed by dividing the average distance between the
two tetracycline labels (in micrometers) by the time interval between the
labeling periods (8 d), and expressed in μm/24 h. Normal values in children
for the parameters measured have been previously reported (20–22).

(b) Bone-derived cell cultures. Trabecular bone specimens obtained
from patient A and from four age-matched controls, i.e., orthopedic
pathological, free from disturbances of calcium and/or phosphorus metab-
olism, were cut into fragments of 1 cm × 1 cm × 2 cm and cut out into
10-cm tissue culture dishes containing modified BGJ medium (Bio-Mé-
riex, Lyon, France) supplemented with 30% fetal calf serum (Flow Labor-
atorics, Puteaux, France), 100 U/ml penicillin, 50 μg/ml streptomycin,
and 2.5 μg/ml fungizone (Boehringer Mannheim Biochemicals, Stras-
bourg, France). After 48 h incubation at 37°C in a humidified atmosphere
of 95% air/5% CO2, the medium containing explants and migrating cells
was filtered through sterile bolting cloth (35-μm mesh). The cell suspen-
sion thus obtained was sedimented at 400 g for 10 min in a desktop
centrifuge (Hettich EBA, Ceralabo, Aubervilliers, France) and the cells
resuspended in BGJ medium containing 10% fetal calf serum. They were
then plated out in 3.5-cm diameter culture dishes (n = 12–20 dishes,
106 cells/dish) in 2 ml modified BGJ medium supplemented with anti-
biotics and 10% fetal calf serum. Medium was renewed every 48 h. The
cells reached confluency after 3 to 5 wk in culture. Confluent cells were
washed once with serum-free BGJ medium and incubated in 2 ml serum-
free BGJ for an additional 6 h before being used for 25-hydroxyvitamin
D3-24-hydroxylase (24-hydroxylase) stimulation and osteocalcin (BGP)
production tests.

24-Hydroxylase assay. The incubation medium was removed and
replaced by 2 ml fresh serum-free medium supplemented with synthetic
1,25(OH)2D3 (final concentration 10−8 M) or its ethanol solvent (not
exceeding 0.2%). After a further incubation period of 18 h at 37°C, cells
were incubated for 90 min in 5% CO2/95% air with 0.1 μCi [3H-26,
27,28]25(OH)D3 (Radiochemical Center, Amersham, United Kingdom;
sp act 18.5 Ci/mmol) in 0.02 ml ethanol. At the end of the incubation,
cells and their incubation medium were transferred to centrifuge tubes
and extracted with methanol-chloroform (2:2, vol/vol). The methanol-
aceous phase was centrifuged for 10 min at 600 g, and the pellet was
washed and stored for determination of DNA content (23). The chloroform
phases were dried under a stream of nitrogen, dissolved in n-hexane-
isopropanol (92:8, vol/vol), and injected into a high pressure liquid chro-
matograph (Waters Associates, Milford, MA) equipped with a sample
injector (model U6K) and a radial compression module RCH 100. The
column, a Radial-Pak B (8 mm × 10 cm) cartridge, was eluted with n-
hexane-isopropanol at a flow rate of 3 ml/min. Fractions of the effluent
were collected every 30 s for 15 min. An aliquot of each collected fraction
was evaporated and dissolved in 5 ml counting solution. Radioactivity
in the fractions was measured using a liquid scintillation spectrometer
model SL30 (Intertechnique, Plaisir, France). The putative 24,25(OH)2D3
metabolite, when detected, was further characterized by co-chromato-
graphy with synthetic 24,25(OH)2D3 on high performance liquid chro-
matography (HPLC) using the above system and a straight-phase system
in which samples were eluted with dichloromethane-isopropanol (95:5,
vol/vol), and by a peridote cleavage procedure (24). Results of the 24-
hydroxylation assay were expressed as femtomeses of [3H]24,25(OH)2D3
formed in 90 min per 10 μg DNA.

Abbreviations used in this paper: BGP, osteocalcin; HPLC, high
performance liquid chromatography; iPTH, immunoreactive parathyroid
hormone; PTH, parathyroid hormone; 24-hydroxylase, 25-hydroxyvi-
tamin D3-24-hydroxylase.
**BGP production.** Cells were incubated for 18 h in serum-free medium supplemented either with 1,25(OH)D$_3$ (10$^{-8}$ M) or its ethanol solvent. The medium was removed and kept frozen before subsequent BGP determination. BGP was measured (Dr. P. Delmas, Hôpital Alexis Carel, Lyon, France) using a previously described modification (25) of the radioimmunoassay described by Price and Nishimoto (26).

Informed consent was obtained from the patient's parents for all the studies and treatment described in accordance with institutional and governmental guidelines.

**Results**

In this patient, who had remained unresponsive to large doses of vitamin D derivatives for 3 yr, two different treatment regimens, i.e., high-calcium high-lactose diet and calcium infusions, were assessed.

**Effect of a high-calcium--high-lactose diet.** The patient was 9-yr-old, weighed 23.2 kg, and measured 113 cm (−3.4 SD) in height when the high-calcium, i.e., 2,250 mg/d, high-lactose, i.e., 62 g/d, diet was initiated. Her skeletal radiograms showed ricketsal alterations, coxa vara, and genu valgum. Previous high-dosage 25(OH)D$_3$ (5 mg/d) therapy had been stopped for 3 mo. The termination of high-dosage 25(OH)D$_3$ therapy induced no significant changes in the biochemical parameters (Table I), although circulating concentrations of 25(OH)D and 1,25(OH)$_2$D decreased from very high levels to 16 ng/ml and 89 pg/ml, respectively. These observations further support the assumption that high-dosage 25(OH)D$_3$ therapy had been totally ineffective from the age of 6 yr. The decrease in serum 25(OH)D concentration observed after termination of high-dosage 25(OH)D$_3$ treatment (Fig. 1) would indicate a circulating half-life of 10 d for this metabolite. This decrease was accompanied by a parallel decrease in serum 1,25(OH)$_2$D concentration with a coefficient of correlation of $r = 0.98$ (p < 0.001). In contrast, no correlation could be found between 25(OH)D and 24,25(OH)$_2$D concentrations.

The high lactose regimen given for 6 mo was well tolerated by the child, except for two short and transient episodes of diarrhea. The regimen had no significant effects on serum calcium and phosphorus concentrations or serum alkaline phosphatase activity (Table I). Serum calcium concentrations remained in the low normal range with low serum phosphorus concentrations, high iPTH, and elevated serum alkaline phosphatase. Urinary calcium excretion was similar on 25(OH)D$_3$ therapy, with no therapy and on the lactose regimen (1.21±0.46, 1.26±0.6, and 1.34±0.18 mg/kg body weight per 24 h, respectively). The deterioration of the physical status of the patient, manifested by loss of appetite, frequent complaints of bone pain, stunted growth, and exaggeration of bony deformities observed during 25(OH)D$_3$ therapy continued without apparent acceleration when this treatment was stopped and during the 6-mo period of the high-calcium--high-lactose diet.

**Effect of nocturnal calcium infusions.** The nocturnal calcium infusion program was carried for 7 mo, initially via an intracaval catheter and later via an arteriovenous fistula. At the end of this period, this treatment was interrupted because the child's arteriovenous fistula required surgical repair because of a stenosis due to fibrosis of the vascular endothelium. After successful repair of her fistula, the patient refused to continue the infusion program. She was left without treatment for 1 mo before high-dosage

---

**Table 1. Biochemical Data during 25(OH)D$_3$ Therapy, After Termination of Treatment, and during the High Calcium–High Lactose Regimen**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>25(OH)D$_3$ (5 mg/d/1 yr)</th>
<th>No therapy (3 mo)</th>
<th>High Ca-high lactose (as 6 mo)</th>
<th>Normal range (serum)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium (mmol/liter)</td>
<td>2.28±0.09 (18)*</td>
<td>2.19±0.09 (11)</td>
<td>2.23±0.06 (11)</td>
<td>2.25-2.60</td>
</tr>
<tr>
<td>Phosphorus (mmol/liter)</td>
<td>0.82±0.09 (18)</td>
<td>0.69±0.07 (11)</td>
<td>0.76±0.09 (11)</td>
<td>1.35-2</td>
</tr>
<tr>
<td>Alkaline phosphatase (IU/liter)</td>
<td>2,030±308</td>
<td>2,138±410</td>
<td>90-300</td>
<td></td>
</tr>
<tr>
<td>Alkaline phosphatase (nkai/liter)</td>
<td>21,526±610 (4)</td>
<td>18,817±201 (11)</td>
<td>1,500-5,000</td>
<td></td>
</tr>
<tr>
<td>iPTH (CaP) (ng/ml)</td>
<td>0.54±0.19 (6)</td>
<td>0.57±0.09 (4)‡</td>
<td>&lt;0.50</td>
<td></td>
</tr>
<tr>
<td>iPTH-(53-84) (pg/ml)</td>
<td>79±25 (4)‡</td>
<td>105±12.6 (5)</td>
<td>15-60</td>
<td></td>
</tr>
<tr>
<td>25(OH)D (ng/ml)</td>
<td>907±366 (14)</td>
<td>765 ±16 (8)§</td>
<td>20±3.1 (3)</td>
<td>6-30</td>
</tr>
<tr>
<td>1,25(OH)$_2$D (pg/ml)</td>
<td>11,012±4,487 (14)</td>
<td>506 ±89 (7)§</td>
<td>106±75 (3)</td>
<td>20-80</td>
</tr>
<tr>
<td>24,25(OH)$_2$D (µg/ml)</td>
<td>2.34±1.28 (16)</td>
<td>2.23±1.61 (8)</td>
<td>0.9-2.3</td>
<td>1-3</td>
</tr>
</tbody>
</table>

* Results are expressed as mean±SD when more than three measurements were made. ‡ When the antithrombin PTH(53-84) serum was used, serum iPTH was measured on the same samples using both the new and the previous CaP antiserum in order to allow comparison of the three studies periods. § The first value corresponds to serum concentration 24 h after the last intake of 25(OH)D$_3$. † The first value for serum 1,25(OH)$_2$D concentrations was obtained 1 wk after termination of 25(OH)D$_3$ therapy. Arrows indicate progressive decreases to values observed at the end of the study period.
(1.5 mg/d) 25(OH)D₃ therapy was prescribed, and she was discharged. Thereafter, she has remained under medical surveillance (Dr. M. Touhami, Clinique A. Cabral, Oran) in Algeria.

The beneficial effects of calcium infusions on the clinical status of the patient was evident as early as 2 wk after the onset of the treatment. The child was relieved of bone pains, recovered her appetite, and became lively again. During her 7-mo therapy she gained 3.35 kg in weight and 3 cm in height vs. 0.9 kg and 2.5 cm, respectively, during the preceding year.

Biochemical parameters (Fig. 2). Repeated monitoring of her serum calcium and phosphorus concentrations, i.e., every 4 h during the infusion, then at the beginning and end of each infusion, and eventually once or twice weekly, showed that serum calcium remained in the normal range except for two transient episodes when it reached 2.65–2.70 mmol/liter. Serum phosphorus concentrations progressively increased and remained in the normal range after 2 mo of treatment. Serum alkaline phosphatase decreased. Normalization of this parameter was obtained in the fourth month of therapy. The generalized hyperaminonaciduria with normal serum amino acid concentration observed before treatment was no longer present in the third month of treatment (not shown). Serum iPTH concentration (Fig. 2) was found to be normal after 6 mo of therapy but increased again to 76 pg/ml when the infusion regimen was stopped. Measurements of circulating vitamin D metabolites concentrations during the whole period of nocturnal infusions showed that 25(OH)D levels remained in the normal range, i.e., 9.3±2.2 ng/ml (n = 7). Serum 1,25(OH)₂D concentrations were usually high, ranging from 33 to 163 pg/ml (112±46 pg/ml, mean±1 SD, n = 6), and serum 24,25(OH)₂D concentrations were variable: low or normal during the first month of calcium infusion, increasing to 4.5 and 7.5 ng/ml in the second and fourth month of therapy, and returning to normal, i.e., 1.4 ng/ml, in the sixth month. The daily amount of calcium excreted in the urine was ∼15–20% of the total calcium infused. This corresponded to a urinary calcium excretion of 6–9 mg/kg body weight per 24 h (range in normal children 0.3–6 mg/kg body weight per 24 h, n = 85).

The skeletal radiograms showed severe metaphyseal abnormalities characteristic of overt rickets and a demineralized bone with coarse trabeculations at the time the calcium infusion was initiated (Fig. 3 A). 3 wk later, the process of healing of these lesions was clearly visible (not shown). Further improvement was observed after 3 mo of nocturnal calcium infusions (not shown), leading to healing of metaphyseal lesions and restoration of a normal trabecular appearance at the end of 4 mo of therapy (Fig. 3 B). Thereafter, repeated radiological examination showed no symptoms of rickets either when the child was changed to a thrice-weekly calcium infusion program or during the 3 mo after termination of this treatment (not shown).

The morphometric data of the three bone biopsies (Table II) confirmed the dramatic changes observed in the skeletal radiograms. The initial biopsy revealed typical histological signs of severe osteomalacia, with excess osteoid volume, increased osteoid surface, and wide osteoid seams associated with a very low percentage of osteoid surface showing a mineralization front. The interface between osteoid and mineralized matrix was sharp in most trabeculae, bearing a few large calcified clusters. Occasionally, the interface was blurred and composed of large zones of fine granules and some osteoid could be observed deep within the calcified matrix. Marrow fibrosis was absent and the percent of trabecular surface covered by osteoclasts was in the normal range. Although the number of osteoclasts was increased, these were inactive in contact with the osteoid tissue. The number of osteoblasts was slightly increased. The second biopsy, obtained after 4 mo of calcium infusion therapy, showed normalization of the osteoid volume and osteoid seam thickness. Osteoid surface had decreased and the extent of the mineralization front was greatly increased as compared with the values obtained in the first biopsy. Moreover, the pattern of mineralization had become normal. The mineralization front appeared as a thin line of fine granules on toluidine-blue-stained sections, and as a clearly defined fluorescent line on unstained sections examined under ultraviolet light. The osteoclast number was found to be in the normal range. On the third biopsy, obtained after cessation of the calcium infusion program, osteomalacia had disappeared. All parameters that reflect matrix formation and mineralization, i.e., osteoid volume, osteoid surface, mineralization front, osteoid width, and mineralization rate, were not different from controls.

Table II. Bone Histomorphometric Data

<table>
<thead>
<tr>
<th></th>
<th>I</th>
<th>II</th>
<th>III</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone volume</td>
<td>21.2</td>
<td>20.6</td>
<td>20.3</td>
<td>24.2±1.6§</td>
</tr>
<tr>
<td>Osteoid volume</td>
<td>24.3</td>
<td>4.1</td>
<td>2.7</td>
<td>3.4±1.5</td>
</tr>
<tr>
<td>Osteoid surface</td>
<td>84.5</td>
<td>50.5</td>
<td>23.9</td>
<td>27.9±9.1</td>
</tr>
<tr>
<td>Mineralization front</td>
<td>9.7</td>
<td>47.3</td>
<td>60.4</td>
<td>70.9±5.3</td>
</tr>
<tr>
<td>Osteoid width (μm)</td>
<td>27.8</td>
<td>8.9</td>
<td>10.7</td>
<td>9.3±3.7</td>
</tr>
<tr>
<td>Osteoblast surface</td>
<td>18.7</td>
<td>12.3</td>
<td>7.3</td>
<td>12.3±3.7</td>
</tr>
<tr>
<td>Osteoclast surface</td>
<td>0.7</td>
<td>0.5</td>
<td>1.1</td>
<td>0.8±0.4</td>
</tr>
<tr>
<td>Osteoclast number/mm²</td>
<td>3</td>
<td>0.7</td>
<td>1.1</td>
<td>0.6±0.2</td>
</tr>
<tr>
<td>Mineralization rate (μm/d)</td>
<td>1.2</td>
<td>1.2</td>
<td>0.2</td>
<td>1.2±0.2</td>
</tr>
</tbody>
</table>

* Iliac crest biopsy I was obtained at initiation of the calcium infusion program; II on day 107 of this treatment; and III 3 mo after the end of this treatment. § Controls values are expressed as mean±SD. Except for the osteoid width, the number of osteoclasts, and the mineralization front, all parameters, as defined in Methods, are expressed as percentages.
Calcium and phosphorus have been documented in all the patients having hereditary resistance to 1,25(OH)\(_2\)D, in whose intestinal absorption of calcium and phosphorus was investigated using external balance studies and/or fractional \(^{47}\)Ca absorption tests (7, 8, 14).

Intestinal absorption of calcium involves two processes, a saturable (active) transfer that is regulated by 1,25(OH)\(_2\)D and a nonsaturable (diffusional) transfer (29, 30). Since, regardless of the activity of the saturable component, calcium absorption by diffusion is a linear function of lumenal calcium concentration, it is possible to overcome intestinal calcium malabsorption, at least in part, by increasing calcium intake. However, during the long-term survey of our patient and of another child with resistance to 1,25(OH)\(_2\)D, it was clear that a slight increase in serum calcium was obtained on a calcium-supplemented diet, but at the expense of a further decrease in serum phosphorus concentrations. Conversely, phosphate supplements augmented serum phosphorus but decreased serum calcium and further stimulated parathyroid hormone secretion (10). The rationale for trying a therapeutic regimen with a calcium- and lactose-enriched diet stemmed from these observations and from experimental evidence showing that lactose enhances intestinal absorption of calcium (31). This calcium- and lactose-rich diet, maintained for nearly 6 mo, was well tolerated by our patient, but its therapeutic action was nil. At the end of this period, when serum 25(OH)D returned to normal levels (16-27 ng/ml), serum 1,25(OH)\(_2\)D concentration was found to be 89-110 pg/ml (Fig. 2). These latter values are still high as compared with those of a normal population, but not as high as those (212-919 pg/ml) reported in some untreated patients (n = 6) with this syndrome and with normal serum 25(OH)D concentrations (5, 7, 11, 12, 32). However, these 1,25(OH)\(_2\)D concentrations in our patient are comparable with the values we reported in another child (10) and to those (83-132 pg/ml) found in seven patients belonging to five unrelated sibships (3, 9, 13, 33). These observations further confirm the great heterogeneity of patients with hereditary resistance to 1,25(OH)\(_2\)D, and indicate that these patients do not necessarily have very high serum 1,25(OH)\(_2\)D concentrations in the untreated state.

The effects of intermittent parenteral calcium infusions were remarkable compared to the ineffectiveness of 3-yr therapy with high-dosage vitamin D derivatives, and the subsequent trial with oral calcium and lactate supplemenations. The decision to in-

Figure 3. Skeletal X-ray data. (A) A wrist radiogram at initiation of the calcium infusion program showed overt signs of rickets, demineralization with coarse trabeculation, and microcysts. A radiogram of the same wrist after 3 wk of treatment demonstrated initiation of heal-

Discussion

The major physiological role of 1,25(OH)\(_2\)D is to act as a calcium-regulating hormone by promoting intestinal absorption of calcium and mobilization of calcium from bone (27, 28). This metabolite also enhances intestinal absorption of phosphorus, independent of its action on the intestinal translocation of calcium. As a consequence, most of the observed biochemical abnormalities in hereditary resistance to 1,25(OH)\(_2\)D, low serum calcium, secondary hyperparathyroidism, increased serum alkaline phosphatase, hyperaminociduria, and in the majority of reported observations, low serum phosphorus, derive either directly or indirectly from disturbances of the intestinal absorption of calcium and of phosphorus. Malabsorption of calcium and of phosphorus has been documented in all the patients having hereditary resistance to 1,25(OH)\(_2\)D, in whose intestinal absorption of calcium and phosphorus was investigated using external balance studies and/or fractional \(^{47}\)Ca absorption tests (7, 8, 14).

Intestinal absorption of calcium involves two processes, a saturable (active) transfer that is regulated by 1,25(OH)\(_2\)D and a nonsaturable (diffusional) transfer (29, 30). Since, regardless of the activity of the saturable component, calcium absorption by diffusion is a linear function of lumenal calcium concentration, it is possible to overcome intestinal calcium malabsorption, at least in part, by increasing calcium intake. However, during the long-term survey of our patient and of another child with resistance to 1,25(OH)\(_2\)D, it was clear that a slight increase in serum calcium was obtained on a calcium-supplemented diet, but at the expense of a further decrease in serum phosphorus concentrations. Conversely, phosphate supplements augmented serum phosphorus but decreased serum calcium and further stimulated parathyroid hormone secretion (10). The rationale for trying a therapeutic regimen with a calcium- and lactose-enriched diet stemmed from these observations and from experimental evidence showing that lactose enhances intestinal absorption of calcium (31). This calcium- and lactose-rich diet, maintained for nearly 6 mo, was well tolerated by our patient, but its therapeutic action was nil. At the end of this period, when serum 25(OH)D returned to normal levels (16-27 ng/ml), serum 1,25(OH)\(_2\)D concentration was found to be 89-110 pg/ml (Fig. 2). These latter values are still high as compared with those of a normal population, but not as high as those (212-919 pg/ml) reported in some untreated patients (n = 6) with this syndrome and with normal serum 25(OH)D concentrations (5, 7, 11, 12, 32). However, these 1,25(OH)\(_2\)D concentrations in our patient are comparable with the values we reported in another child (10) and to those (83-132 pg/ml) found in seven patients belonging to five unrelated sibships (3, 9, 13, 33). These observations further confirm the great heterogeneity of patients with hereditary resistance to 1,25(OH)\(_2\)D, and indicate that these patients do not necessarily have very high serum 1,25(OH)\(_2\)D concentrations in the untreated state.

The effects of intermittent parenteral calcium infusions were remarkable compared to the ineffectiveness of 3-yr therapy with high-dosage vitamin D derivatives, and the subsequent trial with oral calcium and lactate supplemenations. The decision to in-

Parenteral Calcium in Hereditary Resistance to 1,25-Dihydroxyvitamin D 1865
fuse calcium alone and the choice of the dosage of elemental calcium per infusion were derived from previous results. Approximately 100 calcium infusion tests have been performed in children with osteomalacia of various causes (Balsan, S., unpublished data). It was observed that 500–1,000 mg of elemental calcium per one square meter of body surface, infused over 12 h, were well tolerated, increased serum calcium and phosphorus concentrations, and raised the tubular reabsorption of phosphorus. These observations are in agreement with the parathyroid hormone–dependent effect of serum calcium levels on phosphate reabsorption and excretion demonstrated by Eisenberg (34). The present data from our patient with hereditary resistance to 1,25(OH)2D further confirm the previous observations. The 7-mo program of nocturnal calcium infusions normalized the child’s serum calcium concentrations, progressively increased her serum phosphorus concentration, and eventually led to correction of her biochemical abnormalities and to radiological and histologic healing of her skeletal lesions. Spontaneous remission has been recently reported in a kindred with hereditary resistance to 1,25(OH)2D (35). However, in our patient, the occurrence of a biochemical relapse, i.e., a fall in her serum phosphorus and calcium concentrations and a rise in her serum alkaline phosphatase, observed the fifth and sixth month after cessation of the parenteral calcium infusion program, indicates that the recovery obtained was the consequence of this particular treatment program.

The present results are significant. Because they provide, for the first time, an alternative and effective therapeutic model for those patients with hereditary resistance to 1,25(OH)2D who are, or have become during the course of their disease, refractory to high-dosage treatment with vitamin D derivatives. The route of intermittent parenteral administration of calcium must be selected according to the availability of the required facilities and the urgency of active therapy. Calcium infusion via an intracaval catheter provides greater comfort for the child, with no repeated punctures and total freedom of movement, even during sleep. However, such a route can only be used transiently and usually for no longer than 6–9 mo. It also requires adherence to strict rules of asepsis. Consequently, parenteral calcium infusions via an intracaval catheter should never be used in departments that do not possess a highly specialized unit with a medical and nursing staff trained for such treatment. To date, hemodialysis centers are much more numerous and widespread than parenteral nutrition units. Hence, it can be assumed that, for most patients, the route of administration selected will be an arteriovenous fistula. The one inconvenience of this route is that a delay of 2–4 wk is usually necessary before the fistula can be used.

The present data also have theoretical implications. Bone is one of the major target tissues of 1,25(OH)2D (27, 28), and specific binding of this metabolite to bone cells has been recently documented (36). It is also well established that 1,25(OH)2D stimulates osteocalcin synthesis (37), and 25(OH)D2-24 hydroxylase (38). Previous studies on cultured fibroblasts from our patient showed abnormalities in cytosol binding and nuclear uptake of [3H]1,25(OH)2D (10). The present investigations with the patient’s bone-derived cells demonstrate the total ineffectiveness of 1,25(OH)2D in stimulating 25(OH)D2-24-hydroxylase activity and BGP synthesis. Thus, these observations confirm the presence of an abnormal 1,25(OH)2D receptor-effector system in her bone cell. Moreover, they show that this abnormality was still present 3 mo after effective healing of her rickets and osteomalacia. While it has been demonstrated in animal studies that vitamin D, and more specifically 1,25(OH)2D3, is not directly necessary for bone growth and mineralization (39–41), such a demonstration had not been made in man. In 1973, Popovtzer et al. (42) showed that intravenous administration of calcium and phosphorus on alternate days, without supplementary vitamin D, could be successfully used to treat the osteomalacia due to vitamin D deficiency in two adult patients. However, methods for the measurement of circulating concentrations of vitamin D metabolites were not available at that time. Hence, it was not possible to verify that these patients had no circulating 1,25(OH)2D and to eliminate a possible permissive role of this metabolite in bone mineralization, independent of its action on calcium homeostasis. If such a role, which still remains to be demonstrated, does exist, it must be via a mechanism that does not involve the hormone receptor-effector system. In effect, our data provide convincing evidence that, in humans, normal mineralization can be achieved even in the absence of a normal 1,25(OH)2D receptor-effector system, provided that normal circulating calcium and phosphorus concentrations are maintained.

Acknowledgments

We thank Drs. M. Touhami and G. Boudra (Oran, Algeria), who referred the patient and have been following up on her since her return home. We are indebted to Dr. O. Parkes for revising the English of our text, and wish to acknowledge the skilful secretarial assistance of Mrs. M. Poitou.

References

10. Balsan, S., M. Garabédian, U. A. Liberman, C. Eil, A. Bourdeau,
Parenteral Calcium in Hereditary Resistance to 1,25-Dihydroxyvitamin D